Company Description
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders.
Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
The company’s preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain.
Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
| Country | United States |
| IPO Date | Feb 17, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Gerald W. Bruce |
Contact Details
Address: 1055 Westlakes Drive, Suite 300 Berwyn, Pennsylvania 19312 United States | |
| Phone | 610-727-4597 |
| Website | virpaxpharma.com |
Stock Details
| Ticker Symbol | VRPX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001708331 |
| CUSIP Number | 928251107 |
| ISIN Number | US9282511073 |
| Employer ID | 82-1510982 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gerald W. Bruce | Chief Executive Officer and Director |
| Dr. Sheila A. Mathias J.D., M.B.A., Ph.D. | Chief Scientific Officer |
| Dr. Jeffrey A. Gudin M.D. | Executive Vice President, Chief Medical Officer and Director |
| Vinay Shah A.C.A., M.B.A. | Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary |
| Shana Panzarella | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2024 | 8-K | Current Report |
| Jul 12, 2024 | D | Notice of Exempt Offering of Securities |
| Jul 10, 2024 | 8-K | Current Report |
| Jul 8, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 8, 2024 | 8-K | Current Report |
| Jul 3, 2024 | 8-K | Current Report |
| Jun 12, 2024 | ARS | Filing |
| Jun 12, 2024 | DEF 14A | Other definitive proxy statements |
| May 23, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 17, 2024 | 8-K | Current Report |